Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05728879 · ClinicalTrials.gov registry record · Early Phase 1
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
A Early Phase 1 study, sponsored by Northwestern University.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT05728879: Clinical Trial Early Phase 1 study, sponsored by Northwestern University.
NCT05728879 is a Early Phase 1 study that has not yet begun recruiting, run by Northwestern University. The registered enrollment target is 30 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05728879, a Early Phase 1 study, has not yet begun recruiting, sponsored by Northwestern University.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This open-label, pilot study will evaluate the tolerance and change in the microbiome from the use of APR-TD011 ((RLF-TD011) wound cleansing spray for the treatment of CTCL skin lesions.
Primary Outcome
Reduction of Staphylococcus aureus relative abundance between baseline and Week 4
Interventions
- COMBINATION_PRODUCT APR-TD011 (RLF-TD011)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2027-01 |
| Est. Completion | 2028-12 |
| Phase | Early Phase 1 |
What is known before NCT05728879 opens enrollment
NCT05728879 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 1 intervention - of which APR-TD011 (RLF-TD011) is the first listed.
NCT05728879 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05728879 about?
NCT05728879 is a clinical study titled "Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution". This open-label, pilot study will evaluate the tolerance and change in the microbiome from the use of APR-TD011 ((RLF-TD011) wound cleansing spray for the treatment of CTCL skin lesions.
What is the current status of trial NCT05728879?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2027-01. Estimated completion is 2028-12.
What interventions are being tested in trial NCT05728879?
The interventions under investigation include: APR-TD011 (RLF-TD011) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05728879?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05728879's enrollment target sits among peer trials
30 807th of 2000 higher than 1,074 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia